Modulating liver cholesterol metabolism by

3-Iodothyronamine

Nasrin KAZEMIPOUR, Neda ESKANDARZADE, Sareh HADIAN1, Saeed NAZIFI*


1Department of Basic Sciences, School of Veterinary Medicine, Shiraz University, 1731, Shiraz 71345, Iran 2Department of Basic Sciences, School of Veterinary Medicine, Shahid Bahonar University, Kerman, Iran 3Department of Clinical Studies, School of Veterinary Medicine, Shiraz University, 1731, Shiraz 71345, Iran



*Sorumlu Yazar / Corresponding Author:

Saeed NAZIFI

e-mail: nazifi@shirazu.ac.ir

Geliş Tarihi / Received:

16 June 2016

Kabul Tarihi / Accepted:

09 November 2016

Key Words:

3-Iodothyronamine, hepatic lipase, HMG- CoA reductase

Abstract

In this study, we attempt to find out whether chronic low dose 3-Iodothyronamine (an endogenous metabolite of thyroid hormone) administration could modulate liver de novo cholesterol synthesis, the same as thyroid hormones. Eighteen male mice were divided randomly into treatment (n=10) and control (n=8) groups. The experimental procedure was applied for 7 days during which test group received T1AM whereas the control group received dimethyl sulfoxide and normal saline. The liver was analyzed for HMG-CoA reductase concentration and hepatic lipase activity whiles cholesterol, LDL and HDL concentrations were measured in the blood serum. There was non-significant decrease in HMG-CoA reductase concentration (224±21.2 versus 187±32.5) in test group compared to control. Interestingly LDL and cholesterol concentrations exhibited significant decrease in test group versus the control. There was non-significant decrease in hepatic lipase activity (771±316 versus 645±317) in test group versus the control. It appears that T1AM reduced serum LDL and cholesterol just like T3 , in contrast, it decreased liver cholesterol biosynthesis contrary to THs.